Voted 2019’s Company
"Most Likely to Succeed”
by the NJ Tech Council
Medality Medical is developing a surgical device and technique to extract fat located inside the abdomen (visceral fat) to reverse type 2 diabetes (which can lead to heart attack, stroke, blindness, kidney failure, amputation – and death).
A worldwide epidemic
According to the journal of Clinical Diabetes and Endocrinology, diabetes is likely the largest epidemic in human history. It is a global epidemic with 425M people currently with this disease (9% of adult population), 352M have pre-diabetes (another 7% of adult population). In the US alone, the Center for Disease Control and Prevention (CDC) estimated that 23.1 million people had diagnosed diabetes in 2015. In a recent study among a large group of US type 2 diabetes patients, where access to therapy is at the highest level, 44% had discontinued their diabetes medications, altogether, at 6 months – the drug therapy necessary to reduce the potential for long-term complications and death! A straightforward surgical alternative may provide a valuable option to address this global epidemic.
 International Diabetes Federation. IDF Diabetes Atlas, 8th edition, 2017, Brussels, Belgium: http://www.diabetesatlas.org
 Evaluation of Treatment Persistence in Individuals with Type 2 Diabetes in a Real-World Setting; WILLIAM T. CEFALU et. al. Diabetes 2018 Jul; 67(Supplement 1): -. https://doi.org/10.2337/db18-135-OR
Medality Medical’s HydraSolve T2D Visceral Fat Extraction System utilizes the unique, proprietary and patented Targeted Cell Separation and Extraction Technology (TC-SET) to apply a stream of warmed, low-pressurized and pulsed saline solution to separate the mesenteric visceral fat cells; while leaving non-fat cells unharmed. The mesenteric visceral fat cells are instantaneously exposed to the energized saline stream inside the opening of the handheld surgical device and are subdivided into small clusters that are immediately extracted out of the abdomen and into a collection canister. The handheld surgical instrument is blunt and rounded to avoid cutting any tissue and the warm (not hot) saline stream is not capable of burning tissue. It applies “just enough energy” to separate the mesenteric visceral fat cells and enable rapid extraction.
Visceral fat deposits are found mainly in the mesentery. The mesentery’s role is so important that two researchers – Dr. Calvin Coffey and Dr. Peter O’Leary suggest that the mesentery deserves to be recognized as a new human organ https://youtu.be/ru2--3NHQiE. Fat deposit in the mesentery also called mesenteric fat has been shown to play an important role in diseases such as type 2 diabetes, metabolic syndrome and cardiovascular disease.
A landmark, National Institutes of Health (NIH) funded, pre-clinical non-human primate study with the unique HydraSolve T2D Visceral Fat Extraction System and associated surgical procedure demonstrated a reversal of insulin resistance, associated with type 2 diabetes, in all experimental baboons.
In early 2018, study results were published in the peer-reviewed journal, Surgery for Obesity and Related Diseases, in an article entitled: Mesenteric visceral lipectomy using tissue liquefaction technology reverses insulin resistance and causes weight loss in baboons. Based upon the non-human primate study results, it is anticipated there will not be any dietary restrictions or nutritional supplementation that is typical for other gastric surgery alternatives.